Details of Drug-Drug Interaction
| Drug General Information (ID: DDI0KIDYZ8) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Frovatriptan | Drug Info | Dihydrocodeine | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antimigraine Agents | Narcotic Analgesics | |||||||
| Structure | |||||||||
| Mechanism of Frovatriptan-Dihydrocodeine Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive CNS depression effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Frovatriptan | Dihydrocodeine | |||||||
| Mechanism 1 | CNS depression effects | CNS depression effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | CNS depression effects | ||||||||
| Factor Description | CNS depressants are drugs that inhibit or suppress brain activity and can reduce mental and physical processes. Excessive CNS depression can lead to decreased heart rate, slow breathing (less than 10 breaths per minute), extreme confusion or loss of memory, nausea and vomiting, poor judgment, blue lips or fingertips, irritability and aggression, and clammy or cold skin. | ||||||||
| Mechanism Description |
|
||||||||
| Additive serotonergic effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Frovatriptan | Dihydrocodeine | |||||||
| Mechanism 2 | Serotonergic effects | Serotonergic effects | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Serotonergic effects | ||||||||
| Factor Description | Serotonergic drugs include a variety of drugs that enhance or mimic the effects of the neurotransmitter serotonin. Excessive serotonergic activation may lead to a condition known as serotonin syndrome, in which high levels of serotonin in the brain cause the following symptoms: changes in blood pressure, coma, fever, increased heart rate, hallucinations, nausea, and seizures. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary. | ||||||||